Daniele, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 9.242
AS - Asia 5.972
EU - Europa 5.204
SA - Sud America 1.626
Continente sconosciuto - Info sul continente non disponibili 599
AF - Africa 274
OC - Oceania 20
Totale 22.937
Nazione #
US - Stati Uniti d'America 8.776
SG - Singapore 2.519
IT - Italia 1.662
CN - Cina 1.310
BR - Brasile 1.274
DE - Germania 995
VN - Vietnam 707
SE - Svezia 648
FR - Francia 442
IE - Irlanda 286
GB - Regno Unito 263
ID - Indonesia 216
BD - Bangladesh 212
CA - Canada 203
IN - India 189
JP - Giappone 189
UA - Ucraina 176
FI - Finlandia 169
RU - Federazione Russa 161
AR - Argentina 151
HK - Hong Kong 146
CI - Costa d'Avorio 113
MX - Messico 100
PL - Polonia 82
TR - Turchia 81
IQ - Iraq 71
NL - Olanda 59
ES - Italia 54
EC - Ecuador 52
KR - Corea 50
ZA - Sudafrica 49
AT - Austria 46
CO - Colombia 43
VE - Venezuela 39
PK - Pakistan 36
BE - Belgio 31
JM - Giamaica 26
SA - Arabia Saudita 26
PE - Perù 21
UZ - Uzbekistan 21
AU - Australia 20
CR - Costa Rica 20
IL - Israele 20
TW - Taiwan 20
JO - Giordania 19
TN - Tunisia 18
MY - Malesia 17
PH - Filippine 17
MA - Marocco 16
HN - Honduras 15
NP - Nepal 15
CL - Cile 14
EG - Egitto 14
GT - Guatemala 14
IR - Iran 14
PT - Portogallo 14
AE - Emirati Arabi Uniti 13
KE - Kenya 13
PR - Porto Rico 13
RO - Romania 13
CZ - Repubblica Ceca 12
PY - Paraguay 12
RS - Serbia 12
TT - Trinidad e Tobago 12
AZ - Azerbaigian 11
CH - Svizzera 11
NI - Nicaragua 11
SV - El Salvador 11
UY - Uruguay 11
DO - Repubblica Dominicana 10
DZ - Algeria 10
LB - Libano 10
ET - Etiopia 9
BB - Barbados 8
GR - Grecia 8
LT - Lituania 8
AL - Albania 7
BO - Bolivia 7
CW - ???statistics.table.value.countryCode.CW??? 7
EE - Estonia 7
NO - Norvegia 6
SN - Senegal 6
BA - Bosnia-Erzegovina 5
MD - Moldavia 5
OM - Oman 5
PS - Palestinian Territory 5
SC - Seychelles 5
AM - Armenia 4
BG - Bulgaria 4
DK - Danimarca 4
HR - Croazia 4
KZ - Kazakistan 4
PA - Panama 4
QA - Qatar 4
TH - Thailandia 4
AO - Angola 3
BF - Burkina Faso 3
BH - Bahrain 3
BS - Bahamas 3
BY - Bielorussia 3
Totale 22.291
Città #
Singapore 1.225
Ashburn 1.220
San Jose 971
Chandler 623
Council Bluffs 284
Beijing 282
Dublin 260
Ho Chi Minh City 246
Rome 222
Los Angeles 208
Hanoi 184
Jakarta 173
Lauterbourg 172
Tokyo 172
Milan 170
Hefei 160
New York 160
Jacksonville 157
Dallas 143
Hong Kong 132
Wilmington 126
San Mateo 123
Abidjan 113
São Paulo 111
Boston 109
Nanjing 109
Dearborn 103
Cambridge 97
Princeton 94
Frankfurt am Main 92
Ann Arbor 90
Santa Clara 89
St Louis 83
Helsinki 80
Moscow 78
Bar Harbor 71
Cattolica 66
Chicago 64
Woodbridge 64
Fairfield 61
Redwood City 61
Warsaw 61
Naples 57
The Dalles 57
Atlanta 56
Houston 56
Seattle 53
Carrboro 48
Nürnberg 48
Kent 47
Tukwila 45
Boardman 44
Nuremberg 44
Phoenix 44
Brooklyn 43
Buffalo 42
Seoul 42
Munich 41
Rio de Janeiro 41
Montreal 40
Nanchang 39
Da Nang 38
Toronto 38
Bari 37
Paris 35
Redmond 35
Chennai 34
London 34
Shanghai 34
Lawrence 33
Marseille 33
North Bergen 32
Guangzhou 31
Denver 30
Curitiba 29
Shenyang 29
Izmir 28
Brasília 27
Bremen 27
Norwalk 27
Orem 27
Turku 26
Changsha 25
Amsterdam 24
Baghdad 24
Belo Horizonte 24
Hangzhou 24
Philadelphia 24
Mexico City 23
Mountain View 23
Washington 23
Brussels 22
Miami 21
Vienna 21
Campinas 20
Kunming 20
Las Vegas 20
Tianjin 20
Amman 19
Bologna 19
Totale 11.056
Nome #
Neuropsichiatria dei disturbi dell’umore. In: Neuroscienze cliniche e del comportamento. Basi neurobiologiche e neuropsicologiche. Psicopatologia funzionale e neuropsichiatria A cura di C. Blundo 601
Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease 380
Basi neuro anatomiche delle funzioni cognitive e del comportamento 277
Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants 246
Unilateral Extradural Motor Cortex Stimulation is Safe and Improves Parkinson's Disease at 1 Year 235
Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review 221
Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease 216
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing 210
Extradural motor cortex stimulation improves gait, speech, and language in a patient with pure akinesia 207
Sexual Behavior in Women with Bipolar Disorder 205
Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation 194
Analysis of blink rate in patients with blepharospasm 190
Spinal cord stimulation may improve gait and cognition in hereditary spastic paraplegia with mental retardation: a case report 189
Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey 186
New insights into the genetic etiology of Alzheimer's disease and related dementias 184
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial 183
Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson’s disease 182
Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. 179
Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life 176
Erratum: The Apolipoprotein E genotype in patients affected by syndromes with focal cortical atrophy (Neuroscience Letters (2001) 303 (87-90) PII: S0304394001016731) 175
Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. 171
Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides 171
Oxidative Stress And Overexpression Of Manganese Superoxide Dismutase In Patients With Alzheimer's Disease. 170
Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease 170
Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention 170
Oral frailty and its determinants in older age: a systematic review 167
High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease 163
Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry 162
Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson’s disease: Need for long-term trials. 159
APOE epsilon 2/epsilon 4 genotype a risk factor for primary progressive aphasia in women 159
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores 159
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease 158
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2) 155
Effects of deep brain stimulation of the subthalamic nucleus on patients with Parkinson's disease: a machine-learning voice analysis 151
Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? 151
Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease 151
Disproportionate Impairment in Naming and Comprehension of Nouns with Relative Sparing of Verbs in a Patient who Survived Herpes Simplex Encephalitis 151
Polymorphism C in the serotonin 1 transporter gene in depression-free elderly patients with vascular dementia 149
The potential of solanezumab and gantenerumab to prevent Alzheimerâ s disease in people with inherited mutations that cause its early onset 142
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease 142
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease 142
Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy 141
Contribution of Mediterranean Diet in the Prevention of Alzheimer's Disease. 141
Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? 140
Cognitive and behavioural changes after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 139
Neuropsychological features of patients with Parkinson’s disease and impulse control disorders 137
An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities 136
Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging 135
Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke 135
The RELN locus in Alzheimer's Disease 134
Social Frailty in the COVID-19 Pandemic Era 133
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients 132
Targeting oral frailty indicators of late-life cognitive disorders and depression: a systematic review 130
Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy 130
Neuroanatomical Correlates of Category-specific Semantic Disorders: A Critical Survey 130
Apolipoprotein E ε4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients 130
Accelerated Long-Term Forgetting Limited to the Recollection Component of Recognition Memory in a Temporal Lobe Epileptic Patient 129
Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy 127
Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease 126
Malattia di Parkinson e altri disordini del movimento 124
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease 121
Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium 121
Early rightwards orienting of attention on simple reaction time performance in patients with left-sided neglect 119
Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review 119
Cognitive frailty: definitions, components, and impact on disability and mortality 119
Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease? 118
Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease 117
Clusters of cognitive and behavioral disorders clearly distinguish primary progressive aphasia from frontal lobe dementia, and Alzheimer's disease 117
The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes 117
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs 117
Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy 116
Early visual memory deficits: a neuropsychological marker of GBA mutations in PD? 114
Oral frailty indicators and cardio- and cerebrovascular diseases in older age: A systematic review 113
FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia 113
Freezing of gait in Parkinson's disease: the paradoxical interplay between gait and cognition 113
Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging 113
Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs 113
Genotypes and haplotypes in the IL-1 gene cluster: Analysis of two genetically and diagnostically distinct groups of Alzheimer patients 113
Intraoperative Local Field Potential Beta Power and Three-Dimensional Neuroimaging Mapping Predict Long-Term Clinical Response to Deep Brain Stimulation in Parkinson Disease: A Retrospective Study 112
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease 111
Cognitive frailty: a potential target for secondary prevention of dementia 111
The role of biomarkers in psychiatry 110
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease 109
The missing ApoE allele 109
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders 109
Disturbi dell’umore associati a patologie neurologiche: depressione e malattie dei gangli della base 108
Oral frailty and neurodegeneration in Alzheimer's disease 108
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease 107
Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism 107
TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia 105
Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation 105
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease? 105
Impact of periodontal disease on cognitive disorders, dementia, and depression: a systematic review and meta-analysis 104
Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study 104
The Impact of Apolipoprotein E (APOE) Epigenetics on Aging and Sporadic Alzheimer’s Disease 102
Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders 102
Functional disorders after COVID-19 vaccine fuel vaccination hesitancy 102
The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy 102
Association analysis of GRIN2B, encoding N-methyl-D-aspartate receptor 2B subunit, and Alzheimer's disease 101
Disease-modifying therapies for tauopathies: agents in the pipeline 101
Totale 14.905
Categoria #
all - tutte 99.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.345


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022911 0 0 0 71 112 51 28 151 65 53 172 208
2022/20232.086 229 235 170 227 181 258 187 145 249 72 62 71
2023/20241.315 72 362 61 61 75 124 117 51 32 46 147 167
2024/20252.690 56 54 197 105 146 106 75 133 433 277 607 501
2025/20268.803 1.260 267 748 1.198 1.150 400 1.263 500 598 743 395 281
2026/20273.475 507 509 631 1.828 0 0 0 0 0 0 0 0
Totale 22.937